Considerations of pool size in the manufacture of plasma derivatives

Transfusion

Volumn 36, Issue 9, 1996, Pages 770-775

  Lynch, T J ^a   Weinstein, M J ^a,b   Tankersley, D L ^a,b   Fratantoni, J C ^a,b   Finlayson, J S ^a,b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Ctr for Biologics Eval and Res   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; HEPATITIS A VIRUS; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; PARVOVIRUS; PLASMAPHERESIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; VIRUS ACTIVATION;

EID: 0029797490     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36996420751.x     Document Type: Article

References (26)

1. Cohn EJ, Strong LE, Hughes WL Jr, et al. Preparation and properties of serum and plasma proteins. IV: A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Amer Chem Soc 1946;68:459-75.
2. 1-lipoprotein into subfractions of human plasma. J Amer Chem Soc 1949;71:541-50.
3. 21 CFR 640.102(d) (1995).
4. 21 CFR 640, Subpart G (1995).
5. Stirling ML, Murray JA, Mackay P, et al. Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979. J Clin Pathol 1983;36:577-80.
6. Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994;7:279-86.
7. Mortimer PP, Luban NL, Kelleher JF, Cohen BJ. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983;2:482-4.
8. Williams MD, Cohen BJ, Beddall AC, et al. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990;58:177-81.
9. Sokal RR, Rohlf FJ. Biometry, the principles and practice of statistics in biological research. 2nd ed. San Francisco: WH Freeman, 1981:70-82.
10. McOmish F, Yap PL, Jordan A, et al. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993;31:323-8.
11. Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia (letter). Lancet 1992;339:819.
12. Gerritzen A, Schneweis KE, Brackmann HH, et al. Acute hepatitis A in hemophiliacs (letter). Lancet 1992;340:1231-2.
13. Temperley IJ, Cotter KP, Walsh TJ, et al. Clotting factors and hepatitis A (letter). Lancet 1992;340:1466.
14. Peerlinck K, Vermylen J. Acute hepatitis A in patients with haemophilia A (letter). Lancet 1993;341:179.
15. Lusher JM. The hemophilias. In: Rakel RE, ed. Conn's current therapy - 1994. Philadelphia. WB Saunders, 1994:361-72.
16. Lusher JM. Transfusion therapy in congenital coagulopathies. Hematol Oncol Clin North Am 1994;8:1167-80.
17. Aledort LM. Some aspects on the management of hemophilia. Thromb Haemost 1995;74:440-3.
18. Evensen SA, Ulstrup J, Skaug K, et al. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Haematol 1987;39:44-8.
19. Rollag H, Evesen SA, Fröland SS, Glomstein A. Prevalence of antibodies against hepatitis C virus in Norwegians with congenital coagulation factor defects treated with plasma products from small pools. Eur J Clin Microbiol Infect Dis 1990;9:612-4.
20. Rollag H, Patou G, Pattison JR, et al. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991;23:675-9.
21. 21 CFR 211, 606, 610 and 640 (1995).
22. Committee for Proprietary Medicinal Products of the European Community. Medicinal products derived from human blood and plasma. III/8379/89; Dec, 1991.
23. World Health Organization. Good manufacturing practices. Geneva: WHO, 1975: 226, Annex 12.
24. Council of Community Blood Centers. American Red Cross, Baxter and Miles voluntarily withdraw plasma products after donors die of Creutzfeldt-Jakob Disease. CCBC Newsletter 1994; Nov 25:4-6.
25. Food and Drug Administration. Special Advisory Committee on Creutzfeldt-Jakob Disease. June 22, 1995, Bethesda, MD.
26. Leveton LB, Sox HC Jr, Stoto MA, eds. HIV and the blood supply: an analysis of crisis decisionmaking. Washington DC: National Academy Press, 1995.